Jinushi, Ryuhei, Nishiguchi, Sho, Masuda, Sakue et al. · Clinical case reports · 2023 · DOI
This study describes a patient who developed ME/CFS after recovering from COVID-19. The researchers found that this patient had lower-than-normal levels of acylcarnitine, a substance the body uses to produce energy. The study reviews existing research on how COVID-19 can lead to ME/CFS, a condition that causes severe fatigue and symptoms that worsen after physical activity.
This research is important because ME/CFS is difficult to diagnose and lacks established blood tests, making any potential biomarker valuable for patients seeking confirmation of their condition. The connection between COVID-19 and ME/CFS development is increasingly recognized clinically, and identifying metabolic abnormalities like low acylcarnitine may help explain the underlying mechanism of post-exertional malaise.
This case report cannot prove that low acylcarnitine causes ME/CFS or that it occurs in all post-COVID-19 ME/CFS patients—it describes only one individual. The study does not establish whether reduced acylcarnitine is a reliable diagnostic marker or whether it is specific to post-viral ME/CFS versus other conditions. Causation cannot be inferred from a single case observation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.